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Pharmacology
Research Protocol
Risks of harm with cannabinoids, cannabis, and
cannabis-based medicine for pain management
relevant to patients receiving pain treatment:
protocol for an overview of systematic reviews
Ian Gilrona,b,c,*, Fiona M. Blythd, Louisa Degenhardte, Marta Di Fortif,g,h, Christopher Ecclestoni,
Simon Haroutounianj, Andrew Moorek, Andrew S.C. Ricel, Mark Wallacem
Abstract
Introduction: With the increasing availability of cannabis and cannabinoids and their potential utility for pain treatment, there is
a growing need to evaluate the risk-benefit considerations of cannabinoids for the management of pain. As part of the IASP
Cannabis and Cannabinoids Task Force, this protocol describes a planned overview of systematic reviews summarizing the risks of
harm with cannabinoids that are relevant to patients receiving pain treatment.
Methods: This overviewwill involve literature searches of several databases and a defined search strategy that will target systematic
reviews or meta-analyses of cannabinoids where harms are the primary focus. Data extraction will include various features of the
cannabinoid(s) and the harm(s) being studied as well as other methodological features of each included systematic review.
Methodological quality of each included review will be assessed using AMSTAR-2 as well as compliance with the PRISMA harms
checklist. Prospero registration pending.
Discussion: The broad overview of reviews defined by this protocol is expected to synthesize available good quality evidence of
harms that will help inform risk-benefit considerations about the use of cannabinoids for pain management.
Keywords: Cannabis, Cannabinoids, Harms, Adverse events, Adverse effects, Pain management, Clinical trials
1. Introduction
Pain, a common symptom of many acute and chronic health
problems, as well as a disease in its own right in the case
of chronic pain,26 is one of the most costly and disabling
health care problems today.1,5,12,16,24 Due to its complex
biopsychosocial contributing and modulating factors, it has
been long recognized that effective pain management
very often requires a multidisciplinary and multimodal treat-
ment approach.3,6,9,13,14,22 Very few single pain treatments
are highly effective for a majority of pain sufferers,7,17,30
and commonly used treatments such as acetaminophen
(paracetamol), nonsteroidal anti-inflammatory drugs, opioids,
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anticonvulsants, and antidepressants are associated with risks
of serious harms.4,10,15,18 Thus, there is a continued search for
more widely effective, and, perhaps more importantly, safer
pain therapies.25,28,29
With the recognition of analgesic effects of cannabis and
cannabinoids and their potential utility for pain management,2,19
the legalization of cannabis in a growing number of jurisdictions in
the world,27 and an increasing level of prescribing of cannabi-
noids for medicinal purposes in some countries,11 there is
a growing need to carefully evaluate the risk–benefit consid-
erations of cannabinoids for the management of pain. Thus,
the Cannabis and Cannabinoids Task Force was established by
the International Association for the Study of Pain for this
purpose (https://www.iasp-pain.org/About/Content.aspx?Item-
Number57917). The efforts of this task force involve 4 work
packages (WP) to address 4 respective areas of focus: (WP1)
chemical classification, basic pharmacology, and preclinical
evidence of analgesic efficacy; (WP2) synthesis of evidence of
clinical efficacy in painmanagement; (WP3) synthesis of evidence
of harms relevant to patients receiving cannabinoids for pain
management; and (WP4) consideration of societal harms. This
review is intended to focus onWP3. Evidence on harms from pain
management clinical trials is being synthesized by another
ongoing review.21 However, such trials are limited by short
treatment duration and narrowly defined patient populations or
clinical settings. Therefore, this protocol will define a broad
overview of systematic reviews summarizing the risks of harm
with cannabinoids that are relevant to patients receiving pain
treatment.
2. Objectives
The objective of this overview is to synthesize evidence of harms
of cannabinoids—other than the evidence reported in pain
treatment clinical trials—that is relevant to patients receiving
cannabinoids for the management of pain.
3. Methods
This protocol is developed in accordance with PRISMA-P
guidelines20 and will be registered in the PROSPERO register
(protocol number pending).
3.1. Sources of evidence
As an overview of reviews on harms, this broad-spectrum search
protocol targets reviews where harms are the primary focus. We will
search for systematic reviews in PubMed, EMBASE, and
the Cochrane Database of Systematic Reviews. The literature search
strategy is shown in Appendix 1 (available at http://links.lww.com/
PR9/A44). This search strategy was developed with careful
considerationofotherprevious reviewsof cannabinoid-relatedharms,
aswell as previous generic approaches to harms reviews.8 In addition
to the reviews identified by this search strategy, other reviews
identifiedbyhandsearchingof the reviewedarticleswill beconsidered
for inclusion in this overview of reviews.
3.2. Report selection
To be included in this overview, reports were required to be
a systematic review (with or without meta-analysis) focusing on
one or more harms related to cannabinoids (as defined in
Appendix 1, available at http://links.lww.com/PR9/A44) in any
setting that could be considered relevant to patients receiving
cannabinoids for pain management.
3.3. Data extraction
Data extracted from each report will include type(s) of cannabi-
noid(s) evaluated, type(s) of harm(s) evaluated, type(s) of studies
(eg, randomized controlled trials of nonpain conditions, case
series, prospective cohort studies, large database studies,
epidemiological studies etc.), numbers of studies and subjects/
participants included in each review, patient population and/or
clinical setting, specific harm(s) being reported and methods for
their assessment/quantification, cannabinoid being studied (eg,
recreational, medicinal, pharmaceutical, smoked, and ingested),
and reported dosage/duration.
3.4. Quality assessment
For each review included in the overview, methodological quality will
be assessed using AMSTAR-223 as well as evaluating compliance
with items included in thePRISMAharmschecklist.31Other elements
of evidence quality will be evaluated including use of control groups/
comparators, study size, precision/accuracy of cannabinoid expo-
sure, and methodology for the measurement of harm.
4. Discussion
In various national, state, or provincial jurisdictions where
cannabis is legal for medical purposes, cannabis can be
“authorized” for medical purposes, rather than “prescribed,”
because there may be no drug identification number or other
such recognition by the relevant drug regulatory agencies.
However, pharmaceutical cannabinoid agents that have been
approved by drug regulatory agencies for clinical use are indeed
“prescribed.” Patients may receive a variety of cannabinoids to
treat chronic or acute pain either prescribed/dispensed with
direct clinician supervision or self-sought and obtained without
clinician supervision. The most direct evidence of harms would
come from studies in these 2 different settings. However, further
evidence of harms that would be considered relevant to patients
receiving cannabinoids for pain treatment could also come from
settingswhere cannabinoids are prescribed/dispensed for a non-
pain indication or self-sought for recreational use. Thus, the broad
overview of reviews defined by this protocol is expected to
synthesize the available good-quality evidence of harms that will
help inform risk–benefit considerations about the use of
cannabinoids for pain management.
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